Key events include direct-to-consumer drug platform launches tied to the Trump family, court rulings against Novo Nordisk over Medicare negotiations, a massive jury award against Johnson & Johnson, UnitedHealth acquiring a primary care group, Novo Nordisk acquiring Akero Therapeutics, and Bristol Myers Squibb buying Orbital Therapeutics.